Cargando…

Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors

CONTEXT: Aromatase deficiency causes obesity and insulin resistance in aromatase knockout mice and humans with rare mutations of the aromatase gene (CYP19). Aromatase inhibitors are a commonly prescribed therapy for postmenopausal breast cancer. OBJECTIVE: We hypothesized that aromatase inhibitors i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gibb, Fraser W, Dixon, J Michael, Clarke, Catriona, Homer, Natalie Z, Faqehi, Abdullah M M, Andrew, Ruth, Walker, Brian R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Clinical Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642666/ https://www.ncbi.nlm.nih.gov/pubmed/30920624 http://dx.doi.org/10.1210/jc.2018-02339

Ejemplares similares

Aromatase Inhibition Reduces Insulin Sensitivity in Healthy Men
por: Gibb, Fraser W., et al.
Publicado: (2016)

Derivatization of estrogens enhances specificity and sensitivity of analysis of human plasma and serum by liquid chromatography tandem mass spectrometry
por: Faqehi, Abdullah M.M., et al.
Publicado: (2016)

Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors
por: Hong, Dongsheng, et al.
Publicado: (2017)

Derivatization with 2-hydrazino-1-methylpyridine enhances sensitivity of analysis of 5α-dihydrotestosterone in human plasma by liquid chromatography tandem mass spectrometry
por: Faqehi, Abdullah MM, et al.
Publicado: (2021)

Effects of aromatase inhibitor therapy on adiposity and cardiometabolic health in postmenopausal women: a controlled cohort extension study
por: Cheung, Yee-Ming M, et al.
Publicado: (2023)

Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry
por: Upreti, Rita, et al.
Publicado: (2015)

SUBCUTANEOUS ADIPOSE TISSUE INSULIN RESISTANCE IS ASSOCIATED WITH VISCERAL ADIPOSITY IN POSTMENOPAUSAL WOMEN
por: Casey, Beret A., et al.
Publicado: (2014)

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer
por: Kadakia, Kunal C., et al.
Publicado: (2016)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients
por: Jaque, Jenny, et al.
Publicado: (2013)

Effect of Denosumab on Glucose Homeostasis in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors: A Pilot Study
por: Rossini, Alessandro, et al.
Publicado: (2020)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

SAT-009 Proof of Concept That Corticosterone Has a Higher Therapeutic Index Than Hydrocortisone in Patients with Congenital Adrenal Hyperplasia
por: Kyle, Catriona, et al.
Publicado: (2019)

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
por: Yates, R. A., et al.
Publicado: (1996)

Challenges of measuring accurate estradiol levels in aromatase inhibitor‐treated postmenopausal breast cancer patients on vaginal estrogen therapy
por: Niravath, Polly, et al.
Publicado: (2017)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013)

Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
por: Chen, Han, et al.
Publicado: (2020)

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

The Bio-Diversity and the Role of Gut Microbiota in Postmenopausal Women with Luminal Breast Cancer Treated with Aromatase Inhibitors: An Observational Cohort Study
por: Lasagna, Angioletta, et al.
Publicado: (2022)

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
por: Goss, Paul E, et al.
Publicado: (2007)

Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
por: Gonnelli, Stefano, et al.
Publicado: (2008)

Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial
por: Lomax, Anna J., et al.
Publicado: (2013)

Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions
por: Hattori, Yuka, et al.
Publicado: (2015)

Survival Benefit of Zoledronic Acid in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors
por: Ahn, Sung Gwe, et al.
Publicado: (2014)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer
por: Pfeiler, G, et al.
Publicado: (2013)

Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study
por: Iwase, H, et al.
Publicado: (2013)

Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study
por: Harborg, Sixten, et al.
Publicado: (2020)

A higher incidence of smooth endoplasmic reticulum clusters with aromatase inhibitors
por: Saito, Hiroe, et al.
Publicado: (2019)

The Aromatase Gene (CYP19A1) Variants and Circulating Hepatocyte Growth Factor in Postmenopausal Women
por: Lin, Jennifer H., et al.
Publicado: (2012)

Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions
por: Ligibel, Jennifer A, et al.
Publicado: (2005)

Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy
por: Derzko, C., et al.
Publicado: (2007)

Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer
por: Giles, Erin D., et al.
Publicado: (2018)

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
por: Young, Patricia A., et al.
Publicado: (2021)

SAT-024 Adipose Specific Inactivation of Aromatase is Sufficient to Cause Adiposity and Impaired Glucose Tolerance in Mice
por: Oz, Orhan, et al.
Publicado: (2019)

The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model
por: Arumugam, Arunkumar, et al.
Publicado: (2014)

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant
por: Kümler, Iben, et al.
Publicado: (2016)

Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer
por: Martino, Gabriella, et al.
Publicado: (2020)

The effect of exercise training on endothelial function in postmenopausal women with breast cancer under aromatase inhibitor therapy
por: Mayr, Barbara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v2er4q9kcnmqm1h5hoibhj6a1b